Odonate (Odonate) Change In Receivables : $0.00 Mil (TTM As of Sep. 2021)

View and export this data going back to 2017. Start your Free Trial

What is Odonate Change In Receivables?

Odonate's change in receivables for the quarter that ended in Sep. 2021 was $0.00 Mil. It means Odonate's Accounts Receivable stayed the same from Jun. 2021 to Sep. 2021 .

Odonate's change in receivables for the fiscal year that ended in Dec. 2020 was $0.00 Mil. It means Odonate's Accounts Receivable stayed the same from Dec. 2019 to Dec. 2020 .

Odonate's Accounts Receivable for the quarter that ended in Sep. 2021 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Odonate's liquidation value for the three months ended in Sep. 2021 was $60.63 Mil.

Odonate Change In Receivables Historical Data

The historical data trend for Odonate's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Odonate Change In Receivables Chart

Odonate Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Receivables

Get a 7-Day Free Trial

Odonate Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Odonate Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Odonate (OTCPK:ODTCD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Odonate's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Odonate's accounts receivable are only considered to be worth 75% of book value:

Odonate's liquidation value for the quarter that ended in Sep. 2021 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	95.028	-	34.402	+	0.75 * 0	+	0.5 * 0
=	60.63

Odonate Change In Receivables Related Terms

Thank you for viewing the detailed overview of Odonate's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Odonate (Odonate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Odonate Inc (OTCPK:ODTCD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

3 East 28th Street, 10th Floor, New York, NY, USA, 10016

Website

https://www.odonate.com

Odonate Inc is a Shell company.

Executives

Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Boxer Capital, Llc	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Kevin C Tang	director, 10 percent owner, officer: Chief Executive Officer	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Aaron I. Davis	director, 10 percent owner	12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Craig A Johnson	director	C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020
Jeff L Vacirca	director	4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Laura L. Johnson	director	C/O LA JOLLA PHARMACEUTICAL COMPANY, LA JOLLA VILLAGE DRIVE, SUITE 1070, SAN DIEGO CA 92122
Michael S Hearne	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Joseph P O'connell	officer: Chief Medical Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121
Boxer Asset Management Inc.	10 percent owner	CAY HOUSE, EP TAYLOR DRIVE N7776, LYFORD CAY, NEW PROVIDENCE C5 00000
Robert Rosen	director	C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121
Joseph Lewis	10 percent owner	PO BOX N7776, LYFORD BAHAMAS
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
John G Lemkey	officer: Chief Financial Officer	4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO CA 92121